ClinicalTrials.Veeva

Menu
N

National Jewish Health | Clinical Research Services, Denver, CO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

VX-445
Treprostinil
Nintedanib
Trazodone
Omalizumab
N91115
VX-121
Pamrevlumab
Ivacaftor
Sildenafil

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 312 total trials

4D-710 in Adult Patients With Cystic Fibrosis (CF)

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with CF who are ineligible for or una...

Enrolling
Cystic Fibrosis Lung
Biological: 4D-710

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fi...

Enrolling
Cystic Fibrosis
Drug: VX-522 mRNA therapy
Drug: IVA

The primary efficacy objective:To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.The secondary effic...

Enrolling
Idiopathic Inflammatory Myositis
Drug: Daxdilimab
Drug: Placebo

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Atezolizumab
Drug: Lurbinectedin

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) st...

Enrolling
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag
Drug: Placebo

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

Approximately 216 patients with acute pancreatitis and accompanying SIRS will be randomized at approximately 30 sites. Patients will be randomly assi...

Active, not recruiting
Systemic Inflammatory Response Syndrome
Acute Pancreatitis
Drug: CM-4620 Injectable Emulsion or CM-4620-IE
Other: Placebo

IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (d...

Active, not recruiting
Pulmonary Arterial Hypertension
Drug: AV-101
Drug: Placebo

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantama...

Active, not recruiting
Advanced or Metastatic Non-small Cell Lung Cancer
Drug: Lazertinib
Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment w...

Active, not recruiting
Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Nab-paclitaxel

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Astegolimab

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of...

Enrolling
Persistent Infection
Cystic Fibrosis
Drug: Placebo
Drug: CMTX-101

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or pl...

Active, not recruiting
Autoimmune Pulmonary Alveolar Proteinosis
Drug: Placebo
Drug: Molgramostim

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.

Invitation-only
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Inhaled Treprostinil

This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Itepekimab SAR440340

Trial sponsors

National Jewish Health logo
National Institute of Allergy and Infectious Diseases (NIAID) logo
Vertex Pharmaceuticals logo
Penn State Health logo
United Therapeutics logo
Gilead Sciences logo
N
A
Boehringer Ingelheim logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems